Tuberculosis (TB) remains a major global public health problem. According to the World Health Organization (WHO) Global Tuberculosis Report 2025, an estimated 10.7 million people developed TB and approximately 1.23 million died from the disease in 2024. China continues to face a high burden of both TB and multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB)....
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change — this guideline concerns off-label TB pharmacotherapy and has no direct relevance to audiology practice; audiologists should note that some anti-TB drugs (e.g., aminoglycosides) are ototoxic, but this paper does not address ototoxicity monitoring.
Certain anti-tuberculosis drugs carry known ototoxicity (hearing-damage) risk, making TB-treatment guidelines peripherally relevant to audiologists involved in ototoxicity monitoring programmes, but this specific guideline does not address hearing outcomes.
- 01Guidelines cover off-label prescribing of anti-tuberculosis drugs in a Chinese respiratory medicine context.
- 02No audiology, hearing, or ototoxicity content is included in the article.
- 03Some anti-TB drugs (e.g., streptomycin, kanamycin) are known to cause hearing damage, creating an indirect link to audiology.
- 04Published in a Chinese respiratory journal; primary audience is pulmonologists and infectious disease physicians.
- 05No clinical or research relevance to audiology beyond peripheral awareness of ototoxic drug classes.
- PMID
- 42706201
- DOI
- 10.3760/cma.j.cn112147-20251230-00836.
